Novaccess Global Inc XSNX

Healthcare Biotechnology

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

OTCPK:XSNX - Post by User

Novaccess Global Inc > Views on trumps choice to place 30 percent tax on imports?

<< Previous

Bullboard Posts

Next >>

Post by Sdeshwjackstockon Jan 22, 2018 8:06pm

129 Views

Post# 27412144

Views on trumps choice to place 30 percent tax on imports?

I do belive that one of the main reasons why xsunx hasn't made alot of cash is cause its been so much cheeper for people to import from other country's? Is this correct? Now we have more profit capabilities with xsunx?

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market